OA is a severe joint disease that can cause pain, swelling, stiffness, and limited mobility, significantly affecting the quality of life of patients with OA (GOGUET-RUBIO et al. 2017). Previous studies have shown that nitric oxide (NO) donors can produce ROS and activate oxidative stress responses leading to cellular damage in chondrocytes, the cells responsible for maintaining cartilage. This chondrocyte cellular damage reduces cell survival and promotes cell apoptosis (HUANG et al. 2021; XU et al. 2018). In this study, the different concentrations of sodium nitroprusside (SNP) reduced the cell survival rate to about 50% after 12 h of administration. The 1 Mm concentration showed a significant decrease in cell survival, consistent with previous reports.
Furthermore, SNP treatment decreased the expression of autophagy-related proteins, specifically Beclin-1 and ATG5, indicating a reduction in autophagy initiation. IL-1β and LPS are standard drugs for constructing OA cell models in vitro, which can damage C28/I2 chondrocytes by reducing autophagy and inducing apoptosis (XU et al. 2022; JIA et al. 2022). However, whether SNP-mediated cellular oxidative damage can affect autophagy in C28/I2 chondrocytes has not been reported. In our study, we found that different concentrations of SNP could induce the decrease of the expression of autophagy-related proteins Beclin-1 and ATG5 in C28/I2 chondrocytes. Beclin-1 is the first autophagy-related gene discovered, which can directly participate in the formation of autophagy lysosomes, is a critical factor in the regulation of autophagy, and is generally considered a marker of autophagy initiation (VAN et al. 2007). Studies have found that Bcl-2 can bind to the BH3 domain of Beclin-1 so that Bcl-2 can be dissociated from Bax to induce apoptosis. At the same time, the complex formed by Beclin-1 and bcl-2 inhibits the formation of autophagy precursors, thereby reducing the occurrence of autophagy (LIANG et al. 1998). The literature has reported that NO can regulate the formation and degradation of autophagy by interfering with the activity of its C-Jun-N-terminal kinase 1. C-Jun-N-terminal kinase 1 can induce Bcl-2 phosphorylation by affecting the Bcl-2/Beclin − 1, and the formation and dissociation of the Bcl-2/Bax complex affect apoptosis and autophagy. When Bcl-2 is phosphorylated and dissociated from Beclin-1, autophagy is promoted, but Bcl-2 persists. Phosphorylation will inhibit the occurrence of autophagy (WEI et al. 2008). Studies have shown that SNP can promote the expression of the pro-apoptotic protein Bax in chondrocytes and inhibit the expression of Bcl-2 to promote the apoptosis of chondrocytes (LIN et al. 2018). Therefore, as an NO donor, SNP may promote the dissociation of the bcl-2/Beclin-1 complex by regulating the activity of C-Jun-N-terminal kinase 1, thereby promoting the apoptosis of C28/I2 chondrocytes and reducing autophagy. ATG5 is a key protein in the autophagy pathway; it combines with ATG12 to form a protein complex and autophagic vacuoles.
It has been reported that SNP can delay the wound healing of rabbit gastric epithelial cells by inhibiting cell migration and proliferation. These effects may be related to superoxide anion or peroxynitrite, not Cgmp-mediated (KIVILUOTO et al. 2001). Alfke H et al. (ALFKE et al. 2000) found that SNP inhibited primary fibroblast growth factor-stimulated migration of bovine vascular smooth muscle cells in vitro and excluded the side effects of superoxide-derived oxidation products. Zhan R et al. (ZHAN et al. 2015) found that SNP promoted the migration ability of human keratinocyte cell lines through the cGMP signaling pathway and promoted cytoskeleton reorganization by up-regulating the expression of Rho-GTPase. We found that after stimulating C28/I2 chondrocytes with different concentrations of SNP for 12 h, the cell migration ability was reduced, and the cGMP signaling pathway may play a significant role. Still, the exact molecular mechanism needs further research to confirm.
Studies have found that lncRNA participates in the degradation of articular cartilage ECM, inflammation, and inhibition of angiogenesis by regulating autophagy, migration, proliferation, and apoptosis of articular chondrocytes or synoviocytes, thereby affecting the occurrence and development of OA (YUDUSHKIN I. 2020; HUANG. 2020). With the maturity of high-throughput sequencing technology, many lncRNAs differentially expressed in lesioned cartilage tissue have been screened out. However, we have only elucidated a small part of the roles of these differentially expressed lncRNAs, and we need a deeper understanding.
lncRNA MALAT1 was initially discovered in the metastasis-related genes of human non-small cell lung cancer and is involved in various diseases and biological processes. The expression of lncRNA MALAT1 is usually up-regulated in multiple cancers, and up-regulation can promote cell proliferation and inhibit cell apoptosis. In contrast, down-regulation can promote cell apoptosis and inhibit cell proliferation (ZHANG et al. 2019). Studies have reported that the expression of lncRNA MALAT1 is upregulated in glioma stem cells, which enhances the activity and proliferation of cells and promotes the occurrence of glioma tumors (XIONG et al. 2018). In recent years, it has been found that lncRNA MALAT1 can regulate cell autophagy and migration; for example, it is upregulated in breast cancer and promotes autophagy and migration of breast cancer cells (SHIH et al. 2021; XU et al. 2022). Yaxian Song et al. (SONG et al. 2019) studied the expression of lncRNA MALAT1 and found it was upregulated in high glucose-treated endothelial cells. Further studies found that lncRNA MALAT1 affects the expression of NLRP3 by competitively binding miR-22 and promotes elevated glucose-induced endothelial cell apoptosis. However, the biological role of lncRNA MALAT1 in OA is still unclear. It has been reported in the literature that the expression of MALAT1 is up-regulated in OA patient cartilage tissue and SNP-induced chondrocytes, inhibits the viability of chondrocytes, and promotes the degradation of the extracellular matrix of cartilage. When the MALAT1 gene is knocked out, the viability of chondrocytes can be improved (LIU et al. 2019). However, the literature has also reported that the knockout of the MALAT1 gene can inhibit the viability and proliferation of chondrocytes through the PI3K/Akt pathway (LIANG et al. 2018). Our study found SNP-induced upregulation of MALAT1 expression in chondrocytes, consistent with previous reports. However, the difference is that when the MALAT1 gene is knocked out, the survival rate of chondrocytes is improved.
The factors that regulate autophagy in chondrocytes are still not very clear. We have shown that SNPs inhibit autophagy in C28/I2 chondrocytes, and silencing of MALAT1 reverses this trend. The results indicated that MALAT1 was involved in SNP-mediated autophagy in C28/I2 chondrocytes. Studies have found that MALAT1 is also highly expressed in hippocampal neurons of epileptic rats, and the downregulation of MALAT1 activates the PI3K/Akt signaling pathway to protect hippocampal neurons of epileptic rats from autophagy and apoptosis (Wu et al. 2018). Hu H et al. (HU et al. 2019) simulated cardiomyocyte injury with hypoxic injury stimulation and found that MALAT1 expression was increased and cardiomyocyte apoptosis was enhanced by inhibiting autophagy by regulating TSC2-mTOR signaling. It has been reported that the PI3K/Akt/mTOR signaling pathway is closely related to its regulatory effect on OA, and MALAT1 may target the PI3K/Akt/mTOR signaling pathway to regulate SNP-mediated autophagy in C28/I2 chondrocytes.
The literature has reported that when using NO donors to construct oxidatively damaged cells, the concentration needs to reach 0.5–1 mM (KRONCKE et al. 1997). This study found that the cell survival rate reached about 50% when the drug concentration was 1 mM, combined with ATG5 and Beclin-1, two autophagy-related proteins, and cell migration. Finally, it used a 1 mM drug concentration to construct an in vitro OA cell model for subsequent experiments. Many lncRNAs have been shown to play a key role in OA, and we confirmed for the first time that lncRNA MALAT1 plays an essential role in the process of OA by affecting cell autophagy and migration. Our findings provide a basis for studying the exact molecular mechanism of the role of lncRNA MALAT1 in OA and developing new strategies for treating this disease. The multiple effects of lncRNA MALAT1 on chondrocytes indicate that the regulatory network of OA is highly complex, and this gene is expected to be an effective target for the treatment of OA. Finally, animal experiments need to verify further the effect of lncRNA MALAT1 on chondrocytes in vivo.